Shari Bolen, MD, MPH; Leonard Feldman, MD; Jason Vassy, MD, MPH; Lisa Wilson, BS, ScM; Hsin-Chieh Yeh, PhD; Spyridon Marinopoulos, MD, MBA; Crystal Wiley, MD, MPH; Elizabeth Selvin, PhD; Renee Wilson, MS; Eric B. Bass, MD, MPH; Frederick L. Brancati, MD, MHS
Bolen S, Feldman L, Vassy J, Wilson L, Yeh H, Marinopoulos S, et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. Ann Intern Med. 2007;147:386-399. doi: 10.7326/0003-4819-147-6-200709180-00178
Download citation file:
Published: Ann Intern Med. 2007;147(6):386-399.
As newer oral diabetes agents continue to emerge on the market, comparative evidence is urgently required to guide appropriate therapy.
To summarize the English-language literature on the benefits and harms of oral agents (second-generation sulfonylureas, biguanides, thiazolidinediones, meglitinides, and Î±-glucosidase inhibitors) in the treatment of adults with type 2 diabetes mellitus.
The MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched from inception through January 2006 for original articles and through November 2005 for systematic reviews. Unpublished U.S. Food and Drug Administration and industry data were also searched.
216 controlled trials and cohort studies and 2 systematic reviews that addressed benefits and harms of oral diabetes drug classes available in the United States.
Using standardized protocols, 2 reviewers serially abstracted data for each article.
Evidence from clinical trials was inconclusive on major clinical end points, such as cardiovascular mortality. Therefore, the review was limited mainly to studies of intermediate end points. Most oral agents (thiazolidinediones, metformin, and repaglinide) improved glycemic control to the same degree as sulfonylureas (absolute decrease in hemoglobin A1c level of about 1 percentage point). Nateglinide and Î±-glucosidase inhibitors may have slightly weaker effects, on the basis of indirect comparisons of placebo-controlled trials. Thiazolidinediones were the only class that had a beneficial effect on high-density lipoprotein cholesterol levels (mean relative increase, 0.08 to 0.13 mmol/L [3 to 5 mg/dL]) but a harmful effect on low-density lipoprotein (LDL) cholesterol levels (mean relative increase, 0.26 mmol/L [10 mg/dL]) compared with other oral agents. Metformin decreased LDL cholesterol levels by about 0.26 mmol/L (10 mg/dL), whereas other oral agents had no obvious effects on LDL cholesterol levels. Most agents other than metformin increased body weight by 1 to 5 kg. Sulfonylureas and repaglinide were associated with greater risk for hypoglycemia, thiazolidinediones with greater risk for heart failure, and metformin with greater risk for gastrointestinal problems compared with other oral agents. Lactic acidosis was no more common in metformin recipients without comorbid conditions than in recipients of other oral diabetes agents.
Data on major clinical end points were limited. Studies inconsistently reported adverse events other than hypoglycemia, and definitions of adverse events varied across studies. Some harms not assessed in trials or observational studies may have been overlooked.
Compared with newer, more expensive agents (thiazolidinediones, Î±-glucosidase inhibitors, and meglitinides), older agents (second-generation sulfonylureas and metformin) have similar or superior effects on glycemic control, lipids, and other intermediate end points. Large, long-term comparative studies are needed to determine the comparative effects of oral diabetes agents on hard clinical end points.
*Numbers add up to more than the number of abstracts or articles excluded because there may have been more than 1 reason for exclusion. †More than two thirds of the articles that were excluded for having fewer than 40 participants would have been excluded for other reasons as well. ‡The numbers of articles for intermediate outcomes, adverse events, microvascular and macrovascular outcomes, and mortality are not mutually exclusive.
Error bars represent 95% CIs. To convert cholesterol and triglyceride values to mmol/L, multiply by 0.0259 and 0.0113, respectively. Glyb = glyburide; HDL = high-density lipoprotein; LDL = low-density lipoprotein; Met = metformin; Pio = pioglitazone; RCT = randomized, controlled trial; Repag = repaglinide; Rosi = rosiglitazone; SU = sulfonylurea; TZD = thiazolidinedione.
Error bars represent 95% CIs. Glyb = glyburide; Met = metformin; Repag = repaglinide; SU = sulfonylurea; TZD = thiazolidinedione.
Appendix Table 1.
Appendix Table 2.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Other Audio Options: Download MP3
Cardiology, Endocrine and Metabolism, Diabetes, High Value Care, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only